Reactogenicity and immunogenicity study of two doses of GSK [GlaxoSmithKline] Biologicals' oral live attenuated HRV vaccine [RIX 4414] co-administered with either OPV [poliovirus vaccine live oral] or IPV [poliovirus vaccine inactivated] in healthy infants (approximately 5-10 weeks old) in South Africa

Trial Profile

Reactogenicity and immunogenicity study of two doses of GSK [GlaxoSmithKline] Biologicals' oral live attenuated HRV vaccine [RIX 4414] co-administered with either OPV [poliovirus vaccine live oral] or IPV [poliovirus vaccine inactivated] in healthy infants (approximately 5-10 weeks old) in South Africa

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2016

At a glance

  • Drugs Hib-DTaP vaccine; Hib-DTaP-poliovirus vaccine; Poliovirus vaccine live oral; RIX 4414
  • Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Rotavirus infections; Tetanus
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top